(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

18 Suppliers, 10 USDMF, 6 CEP/COS, 4 NDC API, 9 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

DOSSIERs // Finished Dosage Forms

64 Dossiers, 40 FDA Orange Book, 18 Canada, 3 South Africa, 3 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL-28 - 0.035MG;0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

MARKET PLACE

1 APIs

1 APIs

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 2 EDQM Standards, 2 USP Standards, 3 Other Ref. Standards

DIGITAL CONTENT

13 News

13 News

(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
EDQM Standards
Full Screen View

List of EP (Ph. Eur) reference standards related to (17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime

(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

18 Suppliers

10 USDMF

6 CEP/COS

4 NDC API

9 Listed Suppliers

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Imports

DOSSIERs // Finished Dosage Forms

64 Dossiers

40 FDA Orange Book

18 Canada

3 South Africa

3 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL-28 - 0.035MG;0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

MARKET PLACE

1 APIs

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods

2 EDQM Standards

2 USP Standards

3 Other Ref. Standards

DIGITAL CONTENT

13 News

(17-alpha)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime

EDQM, Council of Europe

Norgestimate for system suitability

35189-28-7

5 mg

Y0000725

1

+5°C ± 3°C

1

79

Yes

EDQM, Council of Europe

Norgestimate

35189-28-7

10 mg

Y0000724

1

+5°C ± 3°C

1

79

Yes

TABLET;ORAL-28 - 0.035MG;0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons